Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.86 |
| ▸ | EDNRB | P24530 | 18/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | TSPO | P30536 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891388 | 0.93 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5501162 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380529 | 0.89 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380518 | 0.88 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5497920 | 0.86 | EDNRA (0.87) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380527 | 0.85 | EDNRA (0.85) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380510 | 0.85 | EDNRA (0.81) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5632084 | 0.85 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380528 | 0.84 | EDNRB (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380491 | 0.84 | EDNRA (0.85) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |